You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 66 No. 4, April 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Alzheimer Disease
 •Neurology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Brain Traffic

Subcellular Transport of the Amyloid Precursor Protein

Richard Mayeux, MD, MSc; Peter St. George-Hyslop, MD

Arch Neurol. 2009;66(4):433-434.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The progression from proteolysis of the amyloid precursor protein (APP) to the formation of aggregated amyloid-β peptide (Aβ) deposits forms the basis of the amyloid hypothesis for the pathogenesis of Alzheimer disease.1 Key steps in APP processing occur in subcellular compartments. Amyloid-β is one of several end products that originate from the sequential proteolysis by β-secretase and {gamma}-secretase cleavage of the transmembrane APP. While Aβ can range in size from 37 to 43 amino acids, it is the Aβ42 peptide that appears to be the foundation of fibrillar plaque formation in the brains of patients with Alzheimer disease. Alterations in the intracellular transport of APP can directly influence whether APP undergoes {alpha}-secretase enzymatic activity, releasing a nontoxic peptide, {alpha}-secretase–cleaved soluble APP (sAPP{alpha}), or follows β-secretase and {gamma}-secretase enzymatic pathways, leading to generation of the neurotoxic forms of Aβ. While the {alpha}-secretase . . . [Full Text of this Article]

AUTHOR INFORMATION



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

This Month in Archives of Neurology
Arch Neurol. 2009;66(4):431-432.
FULL TEXT  

Reduction of SorLA/LR11, a Sorting Protein Limiting β-Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid
Qiu-Lan Ma, Douglas R. Galasko, John M. Ringman, Harry V. Vinters, Steven D. Edland, Justine Pomakian, Oliver J. Ubeda, Emily R. Rosario, Bruce Teter, Sally A. Frautschy, and Greg M. Cole
Arch Neurol. 2009;66(4):448-457.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.